<DOC>
	<DOCNO>NCT01456949</DOCNO>
	<brief_summary>The Post-Approval Study ( PAS ) prospective multi-center , non-randomized , single arm , control , unblinded clinical study design provide long-term safety effectiveness Arctic Front® Cardiac CryoAblation System .</brief_summary>
	<brief_title>Sustained Treatment Paroxysmal Atrial Fibrillation Post-Approval Study ( STOP AF PAS )</brief_title>
	<detailed_description>Safety effectiveness evaluate pre-specified performance criterion determine sponsor FDA . The criterion set study previously use demonstrate safety effectiveness cryoablation radio-frequency ablation treatment paroxysmal atrial fibrillation . The analysis primary effectiveness objective take place subject study cryoablation procedure attempt reach 36 month follow-up post-cryoablation procedure . The analysis primary safety objective take place subject study cryoablation procedure attempt reach 12 month follow-up post-cryoablation procedure . The analysis secondary objective take place subject study cryoablation attempt reach 36 month follow-up post-cryoablation procedure .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Documented PAF : Diagnosis paroxysmal atrial fibrillation ( PAF ) , AND 2 episode AF 3 month precede consent Date , AND At least 1 episode AF document trace within 12 month precede consent date . 2 . Age 18 year old 3 . Failure treatment AF ( effectiveness intolerance ) least one membrane active AAD rhythm control . 1 . Any previous leave atrial ( LA ) ablation ( except permissible retreatment subject ) 2 . Any previous LA surgery 3 . Current intracardiac thrombus ( treat thrombus resolve ) 4 . Presence pulmonary vein stent 5 . Presence preexist pulmonary vein stenosis 6 . Preexisting hemidiaphragmatic paralysis 7 . Anteroposterior LA diameter &gt; 5.5 cm TTE 8 . Presence cardiac valve prosthesis 9 . Clinically significant mitral valve regurgitation stenosis 10 . Myocardial infarction , PCI / PTCA coronary artery stenting occur 3 month interval precede Consent Date 11 . Unstable angina 12 . Any cardiac surgery occur 3 month interval precede Consent Date 13 . Any significant congenital heart defect correct ( include atrial septal defect pulmonary vein abnormality include minor PFO ) 14 . NYHA class III IV congestive heart failure 15 . Left ventricular ejection fraction ( LVEF ) &lt; 40 % 16 . 2º ( Type II ) 3º atrioventricular block 17 . Presence permanent pacemaker , biventricular pacemaker , atrial defibrillator type implantable cardiac defibrillator ( without biventricular pace function ) 18 . Brugada syndrome 19 . Long QT syndrome 20 . Arrhythmogenic right ventricular dysplasia 21 . Sarcoidosis 22 . Hypertrophic cardiomyopathy 23 . Known cryoglobulinemia 24 . Uncontrolled hyperthyroidism 25 . Any cerebral ischemic event ( stroke TIAs ) occur 6 month interval precede Consent Date . 26 . Any woman know pregnant 27 . Life expectancy le one ( 1 ) year 28 . Current anticipated participation clinical trial drug , device biologic duration study preapproved Medtronic 29 . Unwilling unable comply fully study procedure followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Atrial fibrillation ( AF )</keyword>
	<keyword>Paroxysmal atrial fibrillation ( PAF )</keyword>
	<keyword>Arrythmias</keyword>
	<keyword>Cardiac Arrythmias</keyword>
	<keyword>Cardiac ablation</keyword>
	<keyword>Cryoablation</keyword>
</DOC>